Skip to content

Search the library by company, product or topic.

↵open↑↓navigateescclose

Owlet

Pediatric monitoring company whose sock-worn sensors report an infant's pulse rate and oxygen level to a phone app, sold over the counter as Dream Sock and on prescription as BabySat.

owletcare.com

At a glance

Headquarters
Lehi, United States
Business model
B2C
Stage
Publicly listed
Products profiled
2
Operating markets
United States
Sources cited
6
In the library since
24 September 2026

What it does

Owlet makes infant monitors worn as a sock: Dream Sock, sold over the counter, and BabySat, which requires a prescription. Both report readings such as pulse rate and oxygen level to a phone app.

Independent evidence

Established from a source other than the company.

FDA records for Owlet Baby Care include the De Novo DEN220091, Dream Sock, granted on 8 November 2023 (product code QYU), and the 510(k) K222597, BabySat 3, cleared on 16 June 2023 (product code DQA). The company is a public filer with the US SEC (NYSE: OWLT), with its business address in Lehi, Utah.

What the company says

The company’s own statements, attributed to it and not presented as established fact.

The company calls Dream Sock the first and only FDA-cleared baby monitor on the market, says its products have been used by more than 2.5 million parents since 2012 and reported second-quarter 2026 revenue of $33.9 million in its results release.

Two company releases name different chief executives: a February 2026 release copy names Jonathan Harris, while the August 2026 results release names Kurt Workman as President, Chief Executive Officer and Co-Founder. No leadership statement is recorded here until the discrepancy is explained. The founding year is not recorded (the 2012 date is a usage date, not a founding statement), and markets outside the United States are not recorded until a market list is read.

Products

More of Recent HealthTech